From beamline to breakthroughs: a review of I03 research

Another method is ribosomal protection, where specific proteins prevent tetracycline from binding to the ribosome, thereby allowing protein synthesis to continue. To counter these defences, modified tetracyclines like tigecycline have been developed, which are designed to evade both efflux and ribosomal protection.

However, a more recent form of resistance has emerged through the action of the Tet(X) enzyme. This enzyme inactivates tetracycline by catalysing its hydroxylation, rendering the antibiotic ineffective and posing a new challenge in the fight against bacterial resistance.

In a recent article published in Chemical Science, researchers from Oxford University developed a new binding assay that enables discovery of new Tet(X) inhibitors. By screening a molecule library, they were able to identify new inhibitors of Tet(X). Crystallographic studies of inhibitors-Tet(X) complexes at Diamond allowed the researchers to reveal the binding mode of the inhibitors. The researchers hope that their new assay will help scientists to create and refine new compounds that can be used to overcome antimicrobial resistance.

Lyme disease, or Lyme borreliosis, is a bacterial infection transmitted to humans through the bite of an infected tick. In England alone, an estimated 3,000 to 4,000 new cases are reported each year. While the disease is generally treatable with antibiotics, some individuals may experience persistent symptoms, such as fatigue, arthritis, or neurological issues, which can last for several years. Although an initial vaccine was developed, it was eventually withdrawn due to limited effectiveness.

In a recent breakthrough, an international team of researchers resolved the structure of a bacterial surface protein called CspZ, which shows promise as a vaccine antigen. This protein helps the bacteria evade the immune system by binding to a complement inhibitor known as factor H. Scientists engineered mutated versions of CspZ to provoke stronger bactericidal responses in mice. Some of these variants also demonstrated improved long-term stability, potentially reducing the need for frequent immunisation.

This study, published in Nature Communications, offers valuable mechanistic insights into structural vaccinology and lays the groundwork for developing next-generation vaccines with enhanced efficacy and durability.

The immune system is a highly complex biological network designed to detect and eliminate foreign invaders such as bacteria, viruses, and fungi. It involves the coordinated activity of over 6,000 genes, maintaining a delicate balance between activation and inhibition. One key player in this regulation is IKZF2, a transcription factor that binds to DNA to control gene expression. This protein is selectively expressed in regulatory T lymphocytes (Tregs), where it plays a role in suppressing immune responses.

Over the past decade, immunotherapies have transformed cancer treatment by harnessing the body’s own immune system to target and destroy tumour cells. However, many cancers have evolved sophisticated mechanisms to evade immune detection. One such strategy involves recruiting Tregs to the tumour microenvironment, which dampens immune activity and reduces the effectiveness of immunotherapies.

In a recent study published in Nature Communications, researchers from the University of Michigan developed a novel compound that acts as a potent and selective molecular glue degrader of IKZF2. This compound binds specifically to IKZF2 and leads to the degradation of over 90% of the protein within cells. In preclinical models, the compound significantly reduced tumour growth in mice and showed a synergistic effect when combined with existing cancer therapies.

This breakthrough offers a promising new approach to enhancing the efficacy of immunotherapies by targeting immune suppression at its source.